RETV804M kinase inhibitor is a selective c-RET (V804M) inhibitor with IC50 value of 20nM.

BT44是一种高选择性 RET 激活剂，能够穿透血脑屏障，适用于神经退行性疾病以及与糖尿病相关的神经系统病变的研究。

RPI-1是一种2-吲哚啉酮Ret酪氨酸激酶抑制剂，具有抗肿瘤作用，能够阻止Ret酪氨酸磷酸化及相关信号通路。

Enbezotinib (enantiomer)是一种RET抑制剂，专门针对RET突变体，具有治疗相关癌症的潜力。

GSK3179106 is a potent, selective and gut-restricted RET kinase inhibitor with IC50 value of 0.4nM.

RET-IN-3是一种选择性 RETV804M 激酶抑制剂，IC₅₀ 值为 19 nM，主要用于 RET 基因突变引发的癌症治疗研究，特别是在甲状腺癌方面的应用。

Blu667 is a highly potent and selective RET inhibitor with IC50 value of 0.4nM.

Selpercatinib是一种选择性RET激酶抑制剂，对多种RET突变型具有显著抑制作用，主要用于治疗RET突变相关的癌症。

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) 是一种有效、选择性、ATP竞争性的口服JAK2抑制剂，对JAK2和JAK2V617F激酶的IC50值均为3 nM。此外，Fedratinib hydrochloride hydrate对JAK1和JAK3的选择性分别为35倍和334倍。它在癌细胞中诱导凋亡，在骨髓增殖性疾病的研究中具有潜力。

Regorafenib（BAY 73-4506）是一种口服活性和高效的多靶点受体酪氨酸激酶抑制剂，对VEGFR1/2/3、PDGFRβ、Kit、RET和Raf-1的IC50值分别为13/4.2/46、22、7、1.5和2.5 nM。Regorafenib显示出强大的抗肿瘤和抗血管生成活性。

AD80 is a multikinase inhibitor with inhibitions on RET, RAF, SRC and S6K.

Fedratinib（TG-101348）是一种强效、选择性、ATP竞争性和口服活性的JAK2抑制剂，对JAK2和JAK2V617F激酶的IC50值均为3 nM。菲达替尼相对于JAK1和JAK3显示出35倍和334倍的选择性。它诱导癌细胞凋亡，并具有潜在的骨髓增殖性疾病研究价值。

JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC50 of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC50s of 180 and 500 nM, respectively .

AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.

CEP-32496 is an inhibitor of BRAF V600E (IC50 = 14 nM), WT (IC50 = 34 nM) and c-Raf (IC50 = 39 nM). It also exhibits certain inhibitory activity against Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2.

Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc.

Regorafenib-d3是一种 Regorafenib 的氘代化合物，Regorafenib 是一种多靶点受体酪氨酸激酶抑制剂。

BBT594 is a potentreceptor tyrosine kinase RET inhibitor, used for cancer treatment.

Pz-1 是一种有效的 RET 和 VEGFR2 受体酪氨酸激酶抑制剂，对野生型激酶的 IC50 值均小于 1 nM。

SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase( IC50 :8 nM). SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.